FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313367778> ?p ?o ?g. }

• W4313367778 endingPage "155396" @default.
• W4313367778 startingPage "155396" @default.
• W4313367778 abstract "Sodium-glucose cotransporter 2 inhibitor (SGLT2i) treatment in type 2 diabetes mellitus patients results in glucosuria, causing an energy loss, and triggers beneficial metabolic adaptations. It is so far unknown if SGLT2i exerts beneficial metabolic effects in prediabetic insulin resistant individuals, yet this is of interest since SGLT2is also reduce the risk for progression of heart failure and chronic kidney disease in patients without diabetes.Fourteen prediabetic insulin resistant individuals (BMI: 30.3 ± 2.1 kg/m2; age: 66.3 ± 6.2 years) underwent 2-weeks of treatment with dapagliflozin (10 mg/day) or placebo in a randomized, placebo-controlled, cross-over design. Outcome parameters include 24-hour and nocturnal substrate oxidation, and twenty-four-hour blood substrate and insulin levels. Hepatic glycogen and lipid content/composition were measured by MRS. Muscle biopsies were taken to measure mitochondrial oxidative capacity and glycogen and lipid content.Dapagliflozin treatment resulted in a urinary glucose excretion of 36 g/24-h, leading to a negative energy and fat balance. Dapagliflozin treatment resulted in a higher 24-hour and nocturnal fat oxidation (p = 0.043 and p = 0.039, respectively), and a lower 24-hour carbohydrate oxidation (p = 0.048). Twenty-four-hour plasma glucose levels were lower (AUC; p = 0.016), while 24-hour free fatty acids and nocturnal β-hydroxybutyrate levels were higher (AUC; p = 0.002 and p = 0.012, respectively) after dapagliflozin compared to placebo. Maximal mitochondrial oxidative capacity was higher after dapagliflozin treatment (dapagliflozin: 87.6 ± 5.4, placebo: 78.1 ± 5.5 pmol/mg/s, p = 0.007). Hepatic glycogen and lipid content were not significantly changed by dapagliflozin compared to placebo. However, muscle glycogen levels were numerically higher in the afternoon in individuals on placebo (morning: 332.9 ± 27.9, afternoon: 368.8 ± 13.1 nmol/mg), while numerically lower in the afternoon on dapagliflozin treatment (morning: 371.7 ± 22.8, afternoon: 340.5 ± 24.3 nmol/mg).Dapagliflozin treatment of prediabetic insulin resistant individuals for 14 days resulted in significant metabolic adaptations in whole-body and skeletal muscle substrate metabolism despite being weight neutral. Dapagliflozin improved fat oxidation and ex vivo skeletal muscle mitochondrial oxidative capacity, mimicking the effects of calorie restriction.ClinicalTrials.gov NCT03721874." @default.
• W4313367778 created "2023-01-06" @default.
• W4313367778 creator A5008766449 @default.
• W4313367778 creator A5015369254 @default.
• W4313367778 creator A5021833046 @default.
• W4313367778 creator A5022874682 @default.
• W4313367778 creator A5025291723 @default.
• W4313367778 creator A5025452926 @default.
• W4313367778 creator A5042240878 @default.
• W4313367778 creator A5049850291 @default.
• W4313367778 creator A5053939956 @default.
• W4313367778 creator A5056617418 @default.
• W4313367778 creator A5060308058 @default.
• W4313367778 creator A5060616620 @default.
• W4313367778 creator A5070391533 @default.
• W4313367778 creator A5086636722 @default.
• W4313367778 creator A5087038295 @default.
• W4313367778 date "2023-03-01" @default.
• W4313367778 modified "2023-10-01" @default.
• W4313367778 title "Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial" @default.
• W4313367778 cites W1127264686 @default.
• W4313367778 cites W1896435085 @default.
• W4313367778 cites W1971004549 @default.
• W4313367778 cites W1971082641 @default.
• W4313367778 cites W1974794804 @default.
• W4313367778 cites W1982509198 @default.
• W4313367778 cites W2021569623 @default.
• W4313367778 cites W2083793966 @default.
• W4313367778 cites W2103416697 @default.
• W4313367778 cites W2111504946 @default.
• W4313367778 cites W2127277443 @default.
• W4313367778 cites W2152927657 @default.
• W4313367778 cites W2153839551 @default.
• W4313367778 cites W2157405334 @default.
• W4313367778 cites W2166613497 @default.
• W4313367778 cites W2168684133 @default.
• W4313367778 cites W2236354758 @default.
• W4313367778 cites W2286556200 @default.
• W4313367778 cites W2338046714 @default.
• W4313367778 cites W2341611738 @default.
• W4313367778 cites W2515456868 @default.
• W4313367778 cites W2618856448 @default.
• W4313367778 cites W2619744261 @default.
• W4313367778 cites W2769428192 @default.
• W4313367778 cites W2777514005 @default.
• W4313367778 cites W2810729752 @default.
• W4313367778 cites W2900413769 @default.
• W4313367778 cites W2921017081 @default.
• W4313367778 cites W2973671909 @default.
• W4313367778 cites W2974260792 @default.
• W4313367778 cites W3004897542 @default.
• W4313367778 cites W3021951994 @default.
• W4313367778 cites W3042187482 @default.
• W4313367778 cites W3045022123 @default.
• W4313367778 cites W3081001956 @default.
• W4313367778 cites W3088173406 @default.
• W4313367778 cites W3112508252 @default.
• W4313367778 cites W3155173216 @default.
• W4313367778 cites W4255692377 @default.
• W4313367778 doi "https://doi.org/10.1016/j.metabol.2022.155396" @default.
• W4313367778 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36592688" @default.
• W4313367778 hasPublicationYear "2023" @default.
• W4313367778 type Work @default.
• W4313367778 citedByCount "5" @default.
• W4313367778 countsByYear W43133677782023 @default.
• W4313367778 crossrefType "journal-article" @default.
• W4313367778 hasAuthorship W4313367778A5008766449 @default.
• W4313367778 hasAuthorship W4313367778A5015369254 @default.
• W4313367778 hasAuthorship W4313367778A5021833046 @default.
• W4313367778 hasAuthorship W4313367778A5022874682 @default.
• W4313367778 hasAuthorship W4313367778A5025291723 @default.
• W4313367778 hasAuthorship W4313367778A5025452926 @default.
• W4313367778 hasAuthorship W4313367778A5042240878 @default.
• W4313367778 hasAuthorship W4313367778A5049850291 @default.
• W4313367778 hasAuthorship W4313367778A5053939956 @default.
• W4313367778 hasAuthorship W4313367778A5056617418 @default.
• W4313367778 hasAuthorship W4313367778A5060308058 @default.
• W4313367778 hasAuthorship W4313367778A5060616620 @default.
• W4313367778 hasAuthorship W4313367778A5070391533 @default.
• W4313367778 hasAuthorship W4313367778A5086636722 @default.
• W4313367778 hasAuthorship W4313367778A5087038295 @default.
• W4313367778 hasBestOaLocation W43133677781 @default.
• W4313367778 hasConcept C126322002 @default.
• W4313367778 hasConcept C134018914 @default.
• W4313367778 hasConcept C142724271 @default.
• W4313367778 hasConcept C204787440 @default.
• W4313367778 hasConcept C27081682 @default.
• W4313367778 hasConcept C2777180221 @default.
• W4313367778 hasConcept C2777391703 @default.
• W4313367778 hasConcept C2777422806 @default.
• W4313367778 hasConcept C2777499176 @default.
• W4313367778 hasConcept C2779306644 @default.
• W4313367778 hasConcept C555293320 @default.
• W4313367778 hasConcept C71924100 @default.
• W4313367778 hasConcept C87813604 @default.
• W4313367778 hasConceptScore W4313367778C126322002 @default.
• W4313367778 hasConceptScore W4313367778C134018914 @default.
• W4313367778 hasConceptScore W4313367778C142724271 @default.

• next